Skip to main content
Fig. 6 | Journal of Hematology & Oncology

Fig. 6

From: Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Fig. 6

Incidence of new or worsening grade 3 or 4 a anemia, b thrombocytopenia, and c leukopenia over time. Anemia, thrombocytopenia, and leukopenia were based on hematologic laboratory abnormalities. (asterisk) Placebo arm data are only shown up to 6 months because all patients randomized to placebo crossed over or discontinued within 3 months of the primary analysis

Back to article page